BioNano Genomics, Inc. (NASDAQ: BNGO) reported Q3 revenue of $3.3 million versus the consensus estimate of $4.44 million.

“Data continue to confirm and validate Saphyr’s potential to replace traditional cytogenetics methods for the detection of structural variants in certain blood cancers, and we are humbled to have globally recognized leaders in their field support the use of Saphyr over traditional methods,” said Erik Holmlin, Ph.D., CEO of Bionano. “We are now seeing Saphyr being accepted and recognized by world-class institutions and expect to see that trend continue. With our recent public offering, we believe we are well-positioned for continued growth.”

For earnings history and earnings-related data on BioNano Genomics, Inc. (BNGO) click here.